Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
50
CADL Quote, Financials, Valuation and Earnings
Last price:
$5.26
Seasonality move
:
8.7%
Day range:
$4.97 - $5.32
52-week range:
$4.25 - $14.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,949.18x
P/B ratio:
3.60x
Volume:
1.4M
Avg. volume:
709.2K
1-year change:
18.74%
Market cap:
$288.8M
Revenue:
--
EPS (TTM):
-$0.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
-- | -$0.17 | -- | -36.82% | $18.63 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -35.16% | -5.21% | $35.78 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
XNCR
Xencor, Inc.
|
$28.7M | -$0.70 | -43.5% | -5.69% | $28.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
$5.26 | $18.63 | $288.8M | -- | $0.00 | 0% | 1,949.18x |
|
MRNA
Moderna, Inc.
|
$25.49 | $35.78 | $10B | -- | $0.00 | 0% | 4.42x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
PFE
Pfizer Inc.
|
$25.70 | $29.04 | $146.1B | 14.98x | $0.43 | 6.69% | 2.34x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
XNCR
Xencor, Inc.
|
$18.14 | $28.00 | $1.3B | -- | $0.00 | 0% | 8.93x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
8.25% | -0.705 | 2.57% | 7.96x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
XNCR
Xencor, Inc.
|
24.45% | 1.841 | 24.19% | 5.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
-$195K | -$13.2M | -32.33% | -38.43% | -- | -$10.4M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
XNCR
Xencor, Inc.
|
$18.4M | -$47.5M | -15.54% | -20.07% | -226.29% | -$31M |
Candel Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CADL or MRNA?
Moderna, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of -19.69%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About CADL or MRNA?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.09%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Candel Therapeutics, Inc. has higher upside potential than Moderna, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 MRNAModerna, Inc.4 15 1 -
Is CADL or MRNA More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock CADL or MRNA?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or MRNA?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $1B. Candel Therapeutics, Inc.'s net income of -$11.3M is higher than Moderna, Inc.'s net income of -$200M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M MRNAModerna, Inc.4.42x -- $1B -$200M
-
Which has Higher Returns CADL or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of -255.85%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CADL or NBY?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.09%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Candel Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CADL or NBY More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CADL or NBY?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or NBY?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns CADL or PFE?
Pfizer Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of 21.32%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About CADL or PFE?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.09%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Candel Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Candel Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 PFEPfizer Inc.7 15 1 -
Is CADL or PFE More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock CADL or PFE?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or PFE?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M PFEPfizer Inc.2.34x 14.98x $16.7B $3.6B
-
Which has Higher Returns CADL or PTN?
Palatin Technologies has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of --. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CADL or PTN?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.09%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Candel Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Candel Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 PTNPalatin Technologies0 0 0 -
Is CADL or PTN More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CADL or PTN?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or PTN?
Candel Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Candel Therapeutics, Inc.'s net income of -$11.3M is higher than Palatin Technologies's net income of --. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CADL or XNCR?
Xencor, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of -28.7%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Xencor, Inc.'s return on equity of -20.07%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M XNCRXencor, Inc.87.62% -$0.08 $827.7M -
What do Analysts Say About CADL or XNCR?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.09%. On the other hand Xencor, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 54.36%. Given that Candel Therapeutics, Inc. has higher upside potential than Xencor, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than Xencor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 XNCRXencor, Inc.9 1 0 -
Is CADL or XNCR More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.
-
Which is a Better Dividend Stock CADL or XNCR?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or XNCR?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than Xencor, Inc.'s net income of -$6M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 8.93x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M XNCRXencor, Inc.8.93x -- $21M -$6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 87.95% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 2.04% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 1.27% over the past day.
